Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Celgene) of lenalidomide (Revlimid(®)), as part of the Single Technology Appraisal (STA) process, to submit evidence for the clinical effectiveness and cost-effectiveness of lenalidomide in combination with rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Witlox, Willem J. A., Grimm, Sabine E., Riemsma, Rob, Armstrong, Nigel, Ryder, Steve, Duffy, Steven, Carrera, Vanesa Huertas, Posadzki, Pawel, Worthy, Gillian, Pouwels, Xavier G. L. V., Ramaekers, Bram L. T., Kleijnen, Jos, Joore, Manuela A., van Asselt, Antoinette D. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867510/
https://www.ncbi.nlm.nih.gov/pubmed/33145711
http://dx.doi.org/10.1007/s40273-020-00971-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867510/
https://www.ncbi.nlm.nih.gov/pubmed/33145711
http://dx.doi.org/10.1007/s40273-020-00971-x

Ejemplares similares